Ivantis Completes a $46.5 MM Financing

▤ Summary

Ivantis, an Irvine, Calif.-based developer of medical device company focused on solutions for glaucoma, raised an additional $14m in Series B funding.The round now totals $46.5m having the company previously announced a $27m first close (read here).Led by Dave Van Meter, President and CEO, Ivantis has developed the novel Hydrus® Microstent device designed to lower eye pressure for glaucoma patients.The Hydrus Microstent, roughly the size of an eyelash, is placed through a minimally invasive, microsurgical procedure.The company recently received approval from the FDA to move from the initial safety phase of its US pivotal trial to the expanded phase.

▦ Linked Companies